Stockscreener 앱 받기
2.75
0.73%
0.02
전일 마감가:
$2.73
열려 있는:
$2.79
하루 거래량:
127.25K
Relative Volume:
0.90
시가총액:
$269.13M
수익:
-
순이익/손실:
$-60.14M
주가수익비율:
-3.876
EPS:
-0.7095
순현금흐름:
$-68.17M
1주 성능:
+4.17%
1개월 성능:
-7.72%
6개월 성능:
-21.20%
1년 성능:
-2.14%
1일 변동 폭
$2.72
$2.81
1주일 범위
$2.60
$2.85
52주 변동 폭
$2.25
$4.9782
Ac Immune Sa Stock (ACIU) Company Profile
ACIU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.75 | 269.13M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.67 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
711.12 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
668.67 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.94 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.01 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-31 | 개시 | BTIG Research | Buy |
| 2019-02-01 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-01-04 | 개시 | UBS | Buy |
| 2018-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-03-23 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | 개시 | Credit Suisse | Outperform |
| 2016-10-18 | 개시 | Jefferies | Buy |
| 2016-10-18 | 개시 | Leerink Partners | Outperform |
모두보기
Ac Immune Sa 주식(ACIU)의 최신 뉴스
Leerink Partnrs Predicts Increased Earnings for AC Immune - MarketBeat
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
New Strong Buy Stocks for January 31st - Yahoo Finance
Five promising small-cap pharmaceutical companies taking on Alzheimer’s - Kursiv Media
AC Immune (NASDAQ:ACIU) & Assembly Biosciences (NASDAQ:ASMB) Head-To-Head Review - Defense World
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Roche, Aelis Farma, AC Immune SA, Eisai Inc., Forest Lab, Eisai Co. - The Globe and Mail
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA - openPR
AC Immune (NASDAQ:ACIU) Shares Cross Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight - The Malaysian Reserve
AC Immune (NASDAQ:ACIU) Shares Down 4.4%Here's What Happened - MarketBeat
US Penny Stocks Spotlight: AC Immune And Two Others To Consider - Yahoo Finance
High Growth Tech Stocks in the United States - Simply Wall St
Broadcom Ltd (AVGO-Q) QuotePress Release - The Globe and Mail
AC Immune SA's (NASDAQ:ACIU) last week's 11% decline must have disappointed retail investors who have a significant stake - Simply Wall St
AC Immune Announces Key Executive Promotions to Strengthen R&D Leadership - TipRanks
AC Immune (NASDAQ:ACIU) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2 - Yahoo Finance
AC Immune's ABATE Trial Shows Positive Safety Data in Down Syndrome - Investing.com Canada
AC Immune Announces Promising Safety Data for Down Syndrome Therapy - TipRanks
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome - GlobeNewswire
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome - GlobeNewswire Inc.
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
AC Immune Q3 2024: Strong Progress and Financial Turnaround - TipRanks
HC Wainwright Reaffirms “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit - Clinical Trials Arena
AC Immune (NASDAQ:ACIU) Given "Buy" Rating at HC Wainwright - MarketBeat
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 - Yahoo Finance
AC Immune (ACIU) Sees Stock Boost Following Positive Trial Data - Stocks Telegraph
Short Interest in AC Immune SA (NASDAQ:ACIU) Increases By 23.5% - MarketBeat
AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October - Defense World
AC Immune stock jumps 20% on data for Parkinson's disease drug (NASDAQ:ACIU) - Seeking Alpha
S&P 500 Moves Lower; US Crude Oil Inventories Increase - Benzinga
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
AC Immune Phase II ACI-7104.056 success in Parkinson’s - The Pharma Letter
AC Immune's Parkinson's vaccine shows promise in early trial - Investing.com India
AC immune announces positive trial results for early Parkinson’s treatment - PharmaTimes
AC Immune’s Promising Trial Results for Parkinson’s Therapy - TipRanks
Immunotherapy in Early Parkinson’s Disease Posts Positive Interim Results from Phase 2 Study - Precision Vaccinations
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune's Parkinson's vaccine shows promise in early trial By Investing.com - Investing.com UK
AC Immune's Parkinson's Drug Shows 16x Higher Antibody Levels in Phase 2 Trial | ACIU Stock News - StockTitan
AC Immune to Present at Jefferies Healthcare Conference: Key Investor Updates Coming | ACIU Stock News - StockTitan
AC Immune to Present at the Jefferies 2024 London Healthcare Conference - Informazione.it
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - The Manila Times
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Yahoo Finance
FY2024 EPS Estimates for AC Immune Lifted by Leerink Partnrs - MarketBeat
Ac Immune Sa (ACIU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
2.97%
자본화:
|
볼륨(24시간):